CMB International: maintains a "buy" rating on TOPSPORTS (06110) with a target price reduced to HK$2.89
China Merchants Securities International is still concerned about the outlook for Tengbo (06110), and believes that there is currently no sign of a turnaround.
CMB International has released a research report, maintaining a "buy" rating on TOPSPORTS (06110) with a target price reduced from HKD 6.78 to HKD 2.89. The new target price reflects a slowdown in industry and Nike-related sales growth, a greater decline in gross profit than expected, and operating leverage weaker than expected. The bank still has concerns about the group's outlook and believes there is currently no sign of a turning point.
The company's latest forecast expects a 35% year-on-year decrease in net profit for the first half of fiscal year 2025. The bank believes the group's performance has been below expectations, mainly due to deleveraging operations, and the company's outlook remains bleak, but the stock dividend remains attractive after the share price decline. The bank notes that TOPSPORTS remains highly cautious about the outlook. Management believes there will be no signs of improvement in the next quarter, or even the entire second half of the fiscal year, based on the sluggish macro environment and drag from some brands. Therefore, CMB International expects the group's retail sales to decline as well as gross profit. There is still a high chance of a more than 30% decline in net profit in the second half of the fiscal year.
Related Articles

China Securities Co., Ltd. reviews the A-share market in the first quarter of 2026: This bull market is more forward-looking in terms of regulation and will take timely measures to address overheated trading.

Jiangsu Aidea Pharmaceutical Group (688488.SH): A clinical trial for a new type 1 drug ACC085 injection in the field of HIV treatment will be conducted.

Subsidiary company of Shenzhen Nanshan Power (000037.SZ) plans to invest in the construction of a 300MW/600MWh independent energy storage power station in the Cuiheng New Area of Zhongshan City (Phases Two and Three) project.
China Securities Co., Ltd. reviews the A-share market in the first quarter of 2026: This bull market is more forward-looking in terms of regulation and will take timely measures to address overheated trading.

Jiangsu Aidea Pharmaceutical Group (688488.SH): A clinical trial for a new type 1 drug ACC085 injection in the field of HIV treatment will be conducted.

Subsidiary company of Shenzhen Nanshan Power (000037.SZ) plans to invest in the construction of a 300MW/600MWh independent energy storage power station in the Cuiheng New Area of Zhongshan City (Phases Two and Three) project.

RECOMMEND

Hong Kong Stocks Surge! Buying Opportunity Or Wait And See? Analysts Provide Comprehensive Interpretation
02/04/2026

Narrative Drives Everything As China’s AI Newcomers Enter An Era Of Extreme Volatility, Retail Investors Flood In
02/04/2026

Fund Cohort Stocks Rally As Institutional Confidence In Hong Kong Equities Shows Signs Of Repair
02/04/2026


